查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552571

前葡萄膜炎治疗市场规模、份额、趋势分析报告：按类型、治疗、分销管道、地区和细分市场预测，2024-2030 年

Anterior Uveitis Treatment Market Size, Share & Trends Analysis Report By Type (Infectious Uveitis), By Therapy (Biologics), By Distribution Channel (Hospital, Retail, Online Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

前葡萄膜炎治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球前葡萄膜炎治疗市场规模将达到9.675亿美元，2024年至2030年复合年增长率为12.6%。

这种疾病盛行率的上升预计将推动市场成长。与全葡萄膜炎、后葡萄膜炎和中间葡萄膜炎相比，这种疾病更常见。

根据《今日视网膜》 2017 年的一篇报导，这种疾病约占葡萄膜炎病例的 30% 至 90%。它还指出，大约 1% 至 4% 的患者视力下降 25%。儘管该疾病有多种有效的治疗方法并且易于管理，但很容易復发。这种疾病多见于青壮年族群。这在老年人中也很常见。眼部缺血和疱疹性葡萄膜炎是老年人群的常见原因。大多数病例发生在健康人群中，但有些病例与感染疾病、胃肠道疾病、风湿病、肺病和皮肤病有关。儘管这种疾病比后葡萄膜炎对视力的威胁较小，但在某些情况下可引起青光眼、白内障和黄斑囊黄斑部水肿。

前葡萄膜炎治疗市场报告亮点

  • 2023 年的前葡萄膜炎治疗市场将由皮质类固醇主导，因为它们具有减少眼部发炎的有益特性。皮质类固醇是主要的治疗工具。
  • 由于抗 TNF 药物生物製药治疗方法机会的扩大，预计抗 TNF 药物在预测期内将表现出良好的成长率。
  • 由于免疫抑制剂越来越多地用于治疗慢性前葡萄膜炎，因此在 2023 年占据了重要的市场占有率。
  • 2023 年的市场将由提供多种治疗选择的医院药房主导
  • 由于折扣产品的便利性、易用性和可用性，预计线上药局在预测期内将呈现显着的复合年增长率。
  • 由于该地区的高盛行率和医疗保健支出，北美在 2023 年占据了最大的销售份额。
  • 由于该地区新兴国家的感染疾病增加和可支配收入增加，预计亚太地区在预测期内将呈现良好的成长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章前葡萄膜炎治疗市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 前葡萄膜炎治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章前葡萄膜炎治疗市场：按类型估计和趋势分析

  • 细分仪表板
  • 前葡萄膜炎治疗市场：2023 年和 2030 年按类型分類的变化分析
  • 传染性葡萄膜炎
  • 非感染性葡萄膜炎

第五章前葡萄膜炎治疗市场：依治疗方法估计与趋势分析

  • 细分仪表板
  • 前葡萄膜炎治疗市场：2023 年和 2030 年治疗的变异分析
  • 皮质类固醇
  • 免疫抑制治疗
  • 生物製药
  • 其他的
  • 管道疗法

第六章前葡萄膜炎治疗市场：按分销管道的估计和趋势分析

  • 细分仪表板
  • 前葡萄膜炎治疗市场：2023 年和 2030 年按分销管道分類的变化分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章前葡萄膜炎治疗市场：区域估计和趋势分析

  • 2023 年和 2030 年前葡萄膜炎治疗市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Novartis AG
    • Santen Pharmaceutical Co., Ltd
    • AbbVie Inc.
    • Kiora Pharmaceuticals, Inc.
    • Clearside Biomedical
    • Aldeyra Therapeutics, Inc.
    • UCB SA
    • Agilent Technologies, Inc.（Lux Biosciences, Inc.）
    • Tarsier Pharma Ltd.
简介目录
Product Code: GVR-3-68038-450-5

Anterior Uveitis Treatment Market Growth & Trends:

The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

Anterior Uveitis Treatment Market Report Highlights:

  • Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.
  • Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.
  • Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.
  • Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.
  • Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.
  • North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.
  • Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Anterior Uveitis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Anterior Uveitis Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Anterior Uveitis Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anterior Uveitis Treatment Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Infectious Uveitis
    • 4.3.1. Infectious Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Non-Infectious Uveitis
    • 4.4.1. Non-Infectious Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.1. Anterior Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.2. Pan-Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.3. Posterior Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.4. Intermediate Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Anterior Uveitis Treatment Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anterior Uveitis Treatment Market: Therapy Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Corticosteroids
    • 5.3.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Immunosuppressive Therapies
    • 5.4.1. Immunosuppressive Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biologics
    • 5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Pipeline Therapies
    • 5.7.1. Pipeline Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Anterior Uveitis Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Anterior Uveitis Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anterior Uveitis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Anterior Uveitis Treatment Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. U K Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Novartis AG
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Santen Pharmaceutical Co., Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AbbVie Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Kiora Pharmaceuticals, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Clearside Biomedical
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Aldeyra Therapeutics, Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. UCB S.A.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Agilent Technologies, Inc. (Lux Biosciences, Inc.)
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Tarsier Pharma Ltd.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives